治疗前原发灶及淋巴结SUVmax对唾液腺癌预后的预测价值
该2中心回顾性研究纳入117例治疗前接受18F-FDG PET/CT的唾液腺癌患者,分析原发灶SUVmax(SUVmax-T)与阳性淋巴结SUVmax(SUVmax-N)与临床结局的关系。中位随访61个月,SUVmax-T和SUVmax-N均以7.0为最佳截断值,≥7者5年LRC、DMFS、PFS和OS均较差(均P<0.001),两者均为独立预测因子,基于两变量的预后评分系统与5年各结局强相关(均P<0.001)。
要点
- 唾液腺癌治疗前原发灶和淋巴结SUVmax均以7.0为PFS最佳截断值。
- SUVmax-T≥7和SUVmax-N≥7者5年LRC、DMFS、PFS、OS均较差(均P<0.001)。
- 基于SUVmax-T和SUVmax-N的预后评分系统与5年各结局强相关(均P<0.001)。
核心结论
- 治疗前18F-FDG PET/CT的原发灶和淋巴结SUVmax可能有助于预测唾液腺癌的治疗结局,尤其当联合用于预后评分系统时。
研究设计与样本
- 2中心回顾性研究,纳入117例2004至2014年间治疗前接受18F-FDG PET/CT并接受根治性治疗的唾液腺癌患者。
主要发现
- 中位随访61个月,5年LRC为78%,DMFS为67%,PFS为62%,OS为68%。
- SUVmax-T和SUVmax-N均以7.0为PFS最佳截断值。
- 与SUVmax-T和SUVmax-N均低于最佳截断值者相比,SUVmax-T和SUVmax-N≥7者5年LRC(P<0.001和P<0.001)、DMFS(P<0.001和P<0.001)、PFS(P<0.001和P<0.001)和OS(P<0.001和P<0.001)率均较差。
- 多因素分析中,SUVmax-T≥7和SUVmax-N≥7均为LRC(P=0.010和0.022)、DMFS(P=0.001和P=0.001)、PFS(P<0.001和P=0.007)和OS(P=0.007和P=0.002)的独立预测因子。
- 基于上述2个变量的预后评分系统与5年LRC、DMFS、PFS和OS率强相关(均P<0.001)。
关键数值与推荐
- SUVmax-T和SUVmax-N预测PFS的最佳截断值均为7.0。
- SUVmax-T≥7为LRC(P=0.010)、DMFS(P=0.001)、PFS(P<0.001)和OS(P=0.007)的独立预测因子。
- SUVmax-N≥7为LRC(P=0.022)、DMFS(P=0.001)、PFS(P=0.007)和OS(P=0.002)的独立预测因子。
- 预后评分系统与5年LRC、DMFS、PFS和OS率均强相关(P<0.001)。
临床怎么用
- 治疗前18F-FDG PET/CT测量的原发灶和淋巴结SUVmax可能作为唾液腺癌预后评估的参考指标。
- 将SUVmax-T和SUVmax-N联合用于预后评分系统可能有助于预测治疗结局。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess whether primary tumor and nodal F-FDG uptake may predict prognosis in patients with salivary gland carcinoma. METHODS: We conducted a 2-center, retrospective study on 117 patients with salivary gland carcinoma who underwent F-FDG PET/CT before treatment and were subsequently treated with curative intent between 2004 and 2014. Pretreatment SUVmax of the primary tumor (SUVmax-T) and that of positive nodes (SUVmax-N) were analyzed in relation to clinical outcomes. RESULTS: Patients were followed up for a median of 61 months. The following 5-year rates were observed: locoregional control (LRC), 78%; distant metastasis-free survival (DMFS), 67%; progression-free survival (PFS), 62%; and overall survival (OS), 68%. A cutoff value of 7.0 maximized the prognostic impact of both SUVmax-T and SUVmax-N for PFS. Compared with patients with SUVmax-T and SUVmax-N values below the optimal cutoff, those with SUVmax-T and SUVmax-N of 7 or greater showed less favorable 5-year LRC (P < 0.001 and P < 0.001), DMFS (P < 0.001 and P < 0.001), PFS (P < 0.001 and P < 0.001), and OS (P < 0.001 and P < 0.001) rates. Both SUVmax-T of 7 or greater and SUVmax-N of 7 or greater were identified as independent predictors of LRC (P = 0.010 and 0.022), DMFS (P = 0.001 and P = 0.001), PFS (P < 0.001 and P = 0.007), and OS (P = 0.007 and P = 0.002) in multivariable analysis. We therefore devised a prognostic scoring system based on these 2 variables, which was found to be strongly associated with 5-year LRC (P < 0.001), DMFS (P < 0.001), PFS (P < 0.001), and OS (P < 0.001) rates. CONCLUSIONS: SUVmax of the primary tumor and SUVmax-N on pretreatment F-FDG PET/CT images may be a useful guide in predicting treatment outcomes, especially when combined in a prognostic scoring system.
引用
- Hsieh CE, Cheng NM, Chou WC, et al. Pretreatment Primary Tumor and Nodal SUVmax Values on 18F-FDG PET/CT Images Predict Prognosis in Patients With Salivary Gland Carcinoma. Clin Nucl Med. 2018. PMID: 30273205. doi:10.1097/RLU.0000000000002287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。